Financial Data and Key Metrics Changes - Schrödinger reported a total revenue of $256 million for 2025, reflecting a 23% growth compared to the previous year [12] - The software business generated approximately $199.5 million in revenue, with an annual contract value (ACV) of $198.5 million, showing strong growth from commercial customers [12][16] - Drug discovery revenue reached $56.4 million, more than doubling from the prior year [12][13] - The net loss for the year was $103 million, an improvement from a net loss of $187 million in 2024 [14] Business Line Data and Key Metrics Changes - Software revenue increased by 11%, while drug discovery revenue more than doubled, indicating balanced growth across business lines [12][13] - Software gross margin was 74%, down from 80% in 2024, due to higher costs associated with contribution revenue from grants [13] - Total operating expenses decreased by approximately 9% to $310 million, reflecting cost reduction initiatives [13] Market Data and Key Metrics Changes - The company experienced a challenging backdrop of tight pharma budgets and difficult biotech capital markets, yet managed to achieve significant revenue growth [12] - The materials science business grew from $15 million to $17 million as new capabilities were introduced [19] Company Strategy and Development Direction - Schrödinger aims to achieve 10%-15% software ACV growth and transition to a primarily hosted model by 2028 [10][24] - The company is focused on expanding its platform capabilities and driving increased adoption through product innovation [10][11] - The strategic pivot initiated last year is expected to position the company for long-term success [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's future, citing strong performance in 2025 and a robust cash position of over $400 million [9][27] - The company anticipates continued growth in drug discovery revenue, targeting approximately $50 million annually [27] - Management acknowledged the challenges in the biotech sector but expects a recovery over the next three years [68] Other Important Information - The company is transitioning to hosted contracts, which will result in more predictable revenue but may compress gross margins in the near term [20][22] - Schrödinger's predictive toxicology solution is expected to drive additional growth, with positive feedback from beta testing [40] Q&A Session Summary Question: Impact of transitioning to hosted contracts on profitability - Management indicated that the goal for profitability by 2028 is based on growth across the software business and disciplined operating expenses [38] Question: Value of predictive toxicology in ACV guidance - Management confirmed that growth from new products, including predictive toxicology, is included in the 10%-15% growth expectation [42] Question: Dynamics of first quarter ACV versus full year - Management explained that Q1 is typically smaller due to customer budgeting cycles, and the full year guidance reflects expected growth [46] Question: Customer engagement with hosted platform transition - Management noted that customers are increasingly preferring hosted deployments, which allow for faster deployment and enhanced support [49] Question: Changes in pharma customer conversations regarding AI - Management stated that the adoption of AI is increasing demand for their software, and they are exploring integration with agentic AI solutions [53][54] Question: Customer split evolution towards ACV growth goal - Management expects recovery in biotech and new product releases to positively impact all customer segments [85]

Financial Data and Key Metrics Changes - Schrödinger reported a total revenue of $256 million for 2025, reflecting a 23% growth compared to the previous year [12] - The software business generated approximately $199.5 million in revenue, with an annual contract value (ACV) of $198.5 million, showing strong growth from commercial customers [12][9] - Drug discovery revenue more than doubled to $56.4 million, indicating successful execution across collaborative programs [12][13] - The net loss for the year was $103 million, an improvement from a net loss of $187 million in 2024 [15] Business Line Data and Key Metrics Changes - Software revenue increased by 11%, while drug discovery revenue saw significant growth, more than doubling compared to the prior year [12][13] - The software gross margin decreased to 74% from 80% in 2024, attributed to higher costs associated with contribution revenue from grants [13] - Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, reflecting cost reduction initiatives [13][14] Market Data and Key Metrics Changes - The company experienced a challenging backdrop of tight pharma budgets and difficult biotech capital markets, yet managed to achieve balanced growth [12] - The materials science business grew from $15 million to $17 million as new capabilities were introduced [20] - The company is targeting additional budgets within existing customers and unlocking opportunities in large markets such as biologics and toxicology [11] Company Strategy and Development Direction - Schrödinger aims to achieve 10%-15% software ACV growth and maintain expense discipline while transitioning to a primarily hosted model [10][26] - The company plans to complete phase 1 studies for SGR-1505 and SGR-3515 and advance collaborative programs [10] - The strategic pivot initiated last year is expected to position the company for long-term success, with a target of achieving positive adjusted EBITDA by the end of 2028 [36][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic direction and the potential for growth driven by new product launches, including the predictive toxicology platform [10][41] - The company views the adoption of AI as a tailwind, increasing demand for its software and enhancing its competitive position [56] - Management acknowledged the challenges in the biotech sector but anticipates a recovery over the next three years [72] Other Important Information - The company is transitioning to hosted contracts, which will result in more predictable revenue but may compress gross margins and adjusted EBITDA in the near term [24][66] - Schrödinger's platform is uniquely positioned to leverage AI in drug and materials discovery, with a focus on physics-based simulations [11][8] Q&A Session Summary Question: Impact of transitioning to hosted contracts on profitability - Management confirmed that the transition to hosted contracts is an ongoing process and remains a critical component of the business strategy [39][40] Question: Growth expectations from new products like Predictive Tox - Management indicated that new products, including Predictive Tox, are expected to contribute to growth, with positive feedback from beta testing [41][42] Question: Customer engagement with the transition to hosted platforms - Management noted that customers are increasingly preferring hosted deployments, which allow for faster deployment and enhanced support [51][52] Question: Assumptions regarding biotech recovery and capital allocation - Management expects a normalization of growth in the biotech sector over the next three years and prefers to invest cash into growth opportunities rather than share buybacks [72][71] Question: Clarification on ACV definition and its impact on revenue - Management explained that ACV reflects the value of contracts, while revenue recognition varies based on contract type, with hosted contracts resulting in more predictable revenue [76][78]